全文获取类型
收费全文 | 742篇 |
免费 | 48篇 |
国内免费 | 24篇 |
专业分类
儿科学 | 26篇 |
妇产科学 | 8篇 |
基础医学 | 84篇 |
口腔科学 | 10篇 |
临床医学 | 50篇 |
内科学 | 380篇 |
皮肤病学 | 30篇 |
神经病学 | 17篇 |
特种医学 | 68篇 |
外科学 | 19篇 |
综合类 | 22篇 |
预防医学 | 9篇 |
药学 | 69篇 |
肿瘤学 | 22篇 |
出版年
2023年 | 3篇 |
2021年 | 4篇 |
2020年 | 2篇 |
2019年 | 12篇 |
2018年 | 11篇 |
2017年 | 3篇 |
2016年 | 4篇 |
2015年 | 13篇 |
2014年 | 13篇 |
2013年 | 24篇 |
2012年 | 33篇 |
2011年 | 17篇 |
2010年 | 20篇 |
2009年 | 25篇 |
2008年 | 37篇 |
2007年 | 67篇 |
2006年 | 39篇 |
2005年 | 39篇 |
2004年 | 35篇 |
2003年 | 28篇 |
2002年 | 24篇 |
2001年 | 22篇 |
2000年 | 21篇 |
1999年 | 25篇 |
1998年 | 25篇 |
1997年 | 19篇 |
1996年 | 30篇 |
1995年 | 13篇 |
1994年 | 18篇 |
1993年 | 14篇 |
1992年 | 10篇 |
1991年 | 12篇 |
1990年 | 20篇 |
1989年 | 15篇 |
1988年 | 20篇 |
1987年 | 11篇 |
1986年 | 13篇 |
1985年 | 12篇 |
1984年 | 7篇 |
1983年 | 7篇 |
1982年 | 7篇 |
1981年 | 7篇 |
1980年 | 5篇 |
1979年 | 3篇 |
1978年 | 3篇 |
1977年 | 4篇 |
1976年 | 6篇 |
1975年 | 3篇 |
1972年 | 3篇 |
1967年 | 2篇 |
排序方式: 共有814条查询结果,搜索用时 15 毫秒
41.
42.
Hanauer SB 《Gastroenterology》2005,129(4):1358-9; author reply 1359
43.
44.
Hanauer SB Sparrow M 《Current opinion in investigational drugs (London, England : 2000)》2004,5(11):1192-1197
COLAL-PRED (prednisolone sodium metasulfobenzoate), which is targeted to the colon by COLAL colonic drug delivery technology, is being developed by Alizyme for the potential treatment of inflammatory bowel disease. Alizyme expect to initiate a phase III trial in 2005. 相似文献
45.
Hanauer SB 《Alimentary pharmacology & therapeutics》2004,20(Z4):60-65
Aminosalicylate therapy for ulcerative colitis remains a foundational strategy for the induction and maintenance of remission for mild to moderate disease. Although it seems clear that topical mesalazine (mesalamine) is the most efficacious approach to distal ulcerative colitis, recent trials with orally delivered azo conjugates suggest that there may be an advantage over pH-released mesalazine as a first-line approach to active disease. No such comparisons are available for azo products and the prolonged-release formulation, Pentasa. However, recent meta-analyses have demonstrated that, although there is little difference in systemic exposure between marketed products, luminal concentrations may vary. In maintenance therapy, aminosalicylates remain the standard approach after aminosalicylate-induced remission. A number of gaps remain in the evidence base with regard to the optimal dosing of oral mesalazine as a maintenance agent, whether oral mesalazine can maintain remissions after rectal mesalazine induction, and the dose-response and efficacy of aminosalicylates after steroid- or ciclosporin-induced remissions. Although aminosalicylates have been advocated for several decades in Crohn's disease, a number of controversies have evolved since the original trials with sulfasalazine in active Crohn's disease. The original trials demonstrated benefits for sulfasalazine in colonic involvement, but controlled trial evidence for the role of sulfasalazine as maintenance therapy has not been as firmly established. In addition, although oral mesalazine has been demonstrated in controlled trials to be superior to placebo in mild to moderate disease, it is less efficacious than corticosteroids at inducing remissions. The maintenance benefits of mesalazine appear to be limited to patients 'induced into remission' with mesalazine and in some post-operative settings. 相似文献
46.
Sandborn WJ Sands BE Wolf DC Valentine JF Safdi M Katz S Isaacs KL Wruble LD Katz J Present DH Loftus EV Graeme-Cook F Odenheimer DJ Hanauer SB 《Alimentary pharmacology & therapeutics》2003,17(11):1355-1364
BACKGROUND: Repifermin (keratinocyte growth factor-2) has been shown to reduce inflammation in animal models of colitis. AIM: To evaluate repifermin for the treatment of active ulcerative colitis. METHODS: Eighty-eight patients with active ulcerative colitis were enrolled in a 6-week, double-blind trial. Patients were randomized to receive treatment for five consecutive days with intravenous repifermin at a dose of 1, 5, 10, 25 or 50 microg/kg, or placebo. The primary objective of the study was to evaluate the safety of repifermin. The primary efficacy outcome was clinical remission at week 4, defined as a score of zero on the endoscopic appearance and stool blood components of the Mayo score and a score of zero or unity on the stool frequency and physician's global assessment components. RESULTS: At week 4, the rates of clinical remission in the 1, 5, 10, 25 and 50 microg/kg repifermin groups were 19%, 9%, 0%, 0% and 0%, respectively, and 11% for the placebo group (P = 0.32 for repifermin vs. placebo). The frequencies of commonly occurring adverse events and severe adverse events were similar in both groups. CONCLUSIONS: Intravenous repifermin at a dose of 1-50 microg/kg was very well tolerated, but there was no evidence that repifermin was effective for the treatment of active ulcerative colitis at these doses. An additional study to determine the efficacy of repifermin at doses of > 50 microg/kg or for a longer treatment duration may be warranted, as the maximally tolerated dose was not reached in the present study. 相似文献
47.
Fecal lactoferrin is a sensitive and specific marker in identifying intestinal inflammation 总被引:12,自引:0,他引:12
Kane SV Sandborn WJ Rufo PA Zholudev A Boone J Lyerly D Camilleri M Hanauer SB 《The American journal of gastroenterology》2003,98(6):1309-1314
OBJECTIVE: Lactoferrin is a glycoprotein expressed by activated neutrophils. The aim of this study was to determine the sensitivity and specificity of fecal lactoferrin concentrations for inflammatory bowel disease (IBD) or irritable bowel syndrome (IBS) versus healthy controls. METHODS: Fresh stool samples were collected from outpatients with ulcerative colitis (UC), Crohn's disease (CD), or IBS. Clinical disease activity for IBD was assessed using a modified Harvey-Bradshaw Activity Index. Fecal lactoferrin concentrations were determined using a polyclonal antibody-based enzyme linked immunoassay. Mean fecal lactoferrin concentrations for each group and sensitivity and specificity of the assay were determined. RESULTS: One hundred-four CD patients, 80 UC patients, 31 IBS patients, and 56 healthy controls were recruited. The mean +/- SE fecal lactoferrin concentration (microg/g fecal weight) was 440 +/- 128 for CD patients, 1125 +/- 498 for UC patients, 1.27 +/- 0.29 for IBS patients, and 1.45 +/- 0.4 for healthy controls. Fecal lactoferrin was 90% specific for identifying inflammation in patients with active IBD. Elevated fecal lactoferrin was 100% specific in ruling out IBS. CONCLUSIONS: Fecal lactoferrin is sensitive and specific for detecting inflammation in chronic IBD. This noninvasive test may prove useful in screening for inflammation in patients presenting with abdominal pain and diarrhea. 相似文献
48.
Smoking and inflammatory bowel disease 总被引:4,自引:0,他引:4
It is well established that smoking cigarettes is associated with Crohn's disease (CD) and that non-smoking is associated with ulcerative colitis (UC). Furthermore, there is convincing evidence that smoking cigarettes has a negative effect on the course of CD, and that smoking cigarettes may improve the disease severity or have a 'protective' effect in some patients with UC. Despite these well-described associations, the mechanism by which cigarette smoking affects CD and UC is not known. Researchers have studied the systemic effects, cellular and humoral immune effects, mucosal changes, and the intestinal permeability changes with inflammatory bowel disease (IBD) and smoking. To date, none of these studies adequately explains the observed clinical patterns. It has been assumed that nicotine is the active agent in these associations, but clinical trials of nicotine chewing gum and transdermal nicotine in UC have shown limited benefit, and have been complicated by significant side-effects. Topical delivery systems for nicotine therapy are currently under development and await future clinical trials. 相似文献
49.
Balsalazide led to greater remission rates and tolerance than mesalamine in acute ulcerative colitis 总被引:2,自引:0,他引:2
下载免费PDF全文
![点击此处可从《Gut》网站下载免费的PDF全文](/ch/ext_images/free.gif)
Hanauer SB 《Gut》1999,44(4):455
50.
Qingxue Wang Judy FC Chow William SB Yeung Estella YL Lau Vivian CY Lee Ernest HY Ng Pak-Chung Ho 《Journal of assisted reproduction and genetics》2014,31(12):1719-1726